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High or persistent exposure to potential
allergens, particularly the house dust mite
antigens, is a major risk factor for the devel-
opment of allergic airway diseases (1).
Although there is an increased understanding
of the mechanisms implicated in the develop-
ment of allergic airway inflammation once
sensitization has occurred, the mechanisms of
interaction between antigens and airway resi-
dent cells and their role in the sensitization
process are still unclear. 
The bronchial epithelium is the first
barrier encountered by inhaled antigens.
Although bronchial epithelial cells express
major histocompatibility complex class II
molecules (2–4), they cannot process antigen
effectively to function as complete accessory
cells (3). Dendritic cells are considered the
main antigen-presenting cells in the airways
(5). For sensitization to occur it is necessary
that potential allergens encounter the cells
that form an intricate network within epithe-
lial cells (5,6). However, the activation of
dendritic cells by inhaled antigens normally
leads to the induction of inhalation tolerance
rather than to allergic inflammation (5–7).
The mechanisms involved in the disruption
of this tolerance in allergic individuals are
poorly understood. One hypothesis is that
antigen-induced activation of resident cells or
other effector cells in the airways may affect
the outcome of antigen exposure through the
release of substances that provide antigen-
presenting cells with specific instruction to
direct the response toward an immune
reaction (7,8). It is therefore important to
clarify how inhaled antigens can interact with
airway epithelial cells and other resident cells
and if the modalities of this interaction are
abnormal in individuals with allergic diseases. 
In this article, I discuss the potential
mechanisms by which antigens may cross the
epithelium and reach their targets in the
bronchial mucosa in order to initiate and reit-
erate allergic responses. I review the results of
studies indicating that bronchial epithelial
cells of patients with allergic asthma behave
differently from normal epithelial cells when
exposed to the antigen most often implicated
in the pathogenesis of this disease and that
this alteration may promote sensitization and
the development of allergic responses. Finally,
I discuss the mechanisms by which inhaled
antigens may potentially affect the cardiovas-
cular function once they have crossed the air-
way epithelium and caused the activation of
airway resident cells. 
Models for Studying Antigen
Trafﬁcking in Airway Epithelial
Cells
The mechanisms by which potential allergens
cross the airway epithelium can be explored
in vitro by using cell lines (9,10) and mono-
layers of airway epithelial cells obtained dur-
ing surgical (9,11) or endoscopic procedures
(endobronchial brushing or biopsy) (12,13)
from individuals who give informed consent. 
The cells from living donors are puriﬁed to
homogeneity according to standard methods
(3,11–13). When cultured at high density
onto collagen-coated polycarbonate filter
inserts, airway epithelial cells conserve their
morphology and function and form well-
differentiated tight junctions after 7–10 days
of incubation (12). The inserts are placed
into the wells of 24-well culture plates to
allow independent access to the apical and to
basolateral compartments of the cells and to
permit monitoring the transepithelial electri-
cal resistance (11,12). The latter is an index
of tight junction integrity and can be mea-
sured by using a microvolt-ohm meter with a
ﬁxed pair of electrodes positioned in the api-
cal and basolateral compartment of the cell
monolayers (11,12). 
In addition to allowing evaluation of
antigen trafficking, the isolation of airway
epithelial cells from their environment enable
the observation of their behavior upon allergen
exposure without the effects of interaction
with other structural cells and inflammatory
cells or their products. Although this represents
a limitation for studies designed to investigate
the relative importance of the mechanisms
involved in airway allergic reactions, which are
based on extensive and complex intercellular
communications, the use of a pure population
of airway epithelial cells is essential for the eval-
uation of potential innate defects. It is particu-
larly important in the search for primary
alterations of bronchial epithelium in allergic
asthma that can explain sensitization and local-
ization of the disease to the airways, e.g.,
abnormal allergen processing (12,13).
Antigen Trafﬁcking and
Aberrant Permeability 
of Asthmatic Epithelium 
Studies employing cultured bronchial epithe-
lial cells or epithelial cell lines have indicated
that certain antigens expressing proteolytic
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activity, such as the major house dust mite
allergen Der p1 (14), can cross the epithelium
by disruption of tight junctions and cell
detachment (9–11). 
An investigation conducted on bronchial
epithelial cells from allergic individuals with
and without asthma has shown that in asth-
matic patients Der p1 can also cross the
epithelium by intracellular movement (12).
The intraepithelial localization of the antigen
was observed within 30 min after the expo-
sure to 1 µg/mL Der p1 in the bronchial
epithelial cells of both asthmatic and nonasth-
matic subjects. After further 30 min of incu-
bation, Der p1 was still detectable in the
internal vesicular bodies or membrane sheets
of cells from asthmatics but disappeared in
the cells of allergic subjects who did not have
asthma. These results suggested that
bronchial epithelial cells of asthmatic patients
may be aberrantly permeable to certain aller-
gens and that this may be due to an innate or
acquired inability to destroy or inactivate
these molecules.
Further studies with epithelial cells from
allergic and healthy donors have revealed that
an intraepithelial transportation of Der p1
occurs also in epithelial cells from individuals
without asthma if the concentration of the
allergen is sufficiently high and the time of
exposure sufficiently long to overcome the
degradation or inactivation process. 
In the experiments illustrated in Figure
1A, bronchial epithelial cells were exposed for
30 min to increasing concentrations of Der p1
in the apical compartment and then re-incu-
bated for 2 hr. In the epithelial cells from
asthmatics, the migration of Der p1 through
the epithelium was evident at concentration as
low as 1 µg/mL. With concentrations of Der
p1 equal to or greater than 50 µg/mL, a
transepithelial migration of the antigen was
also detectable in the cell cultures from allergic
nonasthmatic donors and from healthy con-
trols. The electrical resistance of the monolay-
ers progressively decreased after exposure to
concentrations of Der p1 greater than 10
µg/mL (Figure 1B), indicating that disruption
of the integrity of tight junctions by Der p1
could at least partly account for the move-
ment of Der p1 from the apical to the basolat-
eral compartment at those concentrations. 
Bronchial epithelial cells from asthmatic
patients showed intracellular localization of
Der p1 at 30 and 60 min after exposure to
concentrations of Der p1 as low as 1 µg/mL
for 30 min. At these time points, the antigen
could be respectively detected in the endoso-
mal and lysosomal compartments (Figure 2).
The same pattern of intracellular localization
of the allergen was observed in epithelial cells
of allergic individuals without asthma only
after exposure to 100-fold higher concentra-
tions of Der p1 (Figure 2). This indicated
that an intracellular migration of the antigen
could occur in nonasthmatic bronchial
epithelial cells in addition to the paracellular
migration due to tight junction disruption.
Another set of experiments suggested that
exposure time was an additional important
factor affecting the ability of Der p1 to pene-
trate the bronchial epithelium from different
donors. When exposure to low concentra-
tions of Der p1 (1 µg/mL) was prolonged and
greater than 4 hr, a transepithelial movement
of the antigen could be detected also in the
monolayers from allergic nonasthmatic sub-
jects and from healthy donors (Figure 3A).
This was at least partly due to a disruption of
the tight junctions by Der p1, as it was paral-
leled by a progressive reduction in the
transepithelial resistance (Figure 3B). 
The experiments reported above indicate
that Der p1 can cross the airway epithelium
Figure 1. (A) Concentration-dependent migration of immunoreactive Der p1 across the monolayers of bronchial
epithelial cells from allergic subjects with asthma (AA), allergic subjects without asthma (A) and healthy individuals
(H). Cells were cultured onto collagen-coated polycarbonate filter inserts placed into the wells of 24-well culture
plates, exposed to the indicated concentrations of Der p1 in the apical compartment for 30 min and reincubated for 2
hr. The amounts of immunoreactive Der p1 recovered in the basolateral compartment of the monolayers are
expressed as percentage of the starting concentration in the apical compartment. Der p1 immunoreactivity was eval-
uated by enzyme-linked immunoabsorbent assay (12). (B) Change in electrical resistance from baseline under the
same experimental conditions. Data are means and standard errors from 5 experiments. *p < 0.01 vs A and H; **p <
0.05 vs A and H; ***all p < 0.01 vs control monolayers exposed to Der p1 diluent. 
*
**
40
35
30
25
20
15
10
5
0
0 0.1 1 10 50 100
R
e
c
o
v
e
r
y
 
i
n
 
t
h
e
b
a
s
o
l
a
t
e
r
a
l
 
c
o
m
p
a
r
t
m
e
n
t
 
(
%
) A
Der p1 in the apical compartment (µg/mL)
AA
A
H
●
● ●
B
0 0.1 1 10 50 100
■▲ ●
■▲ ●
■▲ ■▲
■▲
●
■▲
20
0
–20
–40
–60
–80
C
h
a
n
g
e
 
i
n
 
e
l
e
c
t
r
i
c
a
l
 
r
e
s
i
s
t
a
n
c
e
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
%
)
Der p1 in the apical compartment (µg/mL)
AA
A
H ▲
■
●
***
***
Figure 2. Localization of Der p1 in the endosomal and lysosomal compartments of bronchial epithelial cells from one
allergic subject with asthma (AA) and one allergic subject without asthma (A) at the indicated time points following
30-min exposure to 1 and 100 µg/mL Der p1. For these experiments, cells were grown on glass coverslips and Der p1
was labeled with ﬂuorescein isothiocyanate (FITC) before being added to the cells. After exposure, cells were rinsed
in phosphate-buffered saline (PBS) and ﬁxed in methanol/acetic acid. Fixed cells were immersed for 15 min in block-
ing solution containing 5% goat serum and 0.2% Triton-X in PBS, and then incubated for 1 hr with either a mouse
anti-cathepsin D antibody (endosomal marker) or the mouse anti-CD63 antibody (lysosomal marker). The cells were
rinsed repeatedly in PBS, incubated with Texas-red-labeled secondary antibodies, rinsed, and mounted before analy-
sis by ﬂuorescence microscopy. The yellow staining at 30 and 60 min indicates colocalization of Der p1 in the endoso-
mal and lysosomal compartment, respectively (original magnification: × 600). The results are representative of six
separate experiments.
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via both transcellular and paracellular
movements. Nonasthmatic epithelium can
resist the intracellular passage of low concen-
trations of Der p1 that reach its surface for a
short time. The mechanism of this resistance
and the reason it is defective in asthmatic
epithelium remain unknown, but asthmatic
epithelial cells may have an intrinsic defect in
intracellular antiproteases defenses as the
intracellular transport of Der p1 is abolished
by antiproteases (12,13). 
In the same experiments, brief exposure
to high concentrations of an antigen with
proteolytic activity or prolonged exposure
to low concentrations caused disruption of
the tight junctions in bronchial epithelial
cells from asthmatic patients and also in the
cells from nonasthmatic individuals. If this
event also occurs in vivo, it may favor pene-
tration into the airway mucosa of other
antigens devoid of proteolytic activity,
thereby increasing the probability that they
can encounter antigen-presenting cells and
cause sensitization (Figure 4). Such a phe-
nomenon would explain why sensitization
to house dust mite antigens is frequently
associated with sensitization to multiple
antigens (15). 
Antigen-Induced Epithelial
Cell Activation and Mediator
Release
Some studies have revealed that exposure of
airway epithelial cells to Der p1 results in the
release of proinflammatory cytokines and
chemokines, particularly granulocyte-
macrophage colony-stimulating factor (GM-
CSF) (9,12,13), interleukin (IL)-6 (9), and
the protein regulated-on-activation-normal-
T-cell-expressed-and-secreted (RANTES)
(13). The release of these mediators from
bronchial epithelial cells of asthmatic patients
is associated with the intracellular transport of
the allergen and occurs after brief exposure to
low concentrations of Der p1 (12,13). 
In the experiments illustrated in Figure
5A–B, we exposed bronchial epithelial cells
from different donors to either increasing
concentrations of Der p1 for 30 min or to a
ﬁxed concentration of Der p1 (1 µg/mL) for
various periods of time and evaluated the
release of immunoreactive eotaxin. The pat-
tern of eotaxin immunoreactivity was consis-
tent with the results of the experiments on
the transepithelial migration of the antigen
discussed above. Thus, exposure to low con-
centrations of Der p1 for brief periods
induced an appreciable eotaxin release only in
the cultures of epithelial cells from asthmatic
patients. Higher concentrations of the anti-
gen or a prolonged exposure was required to
induce a similar effect in the cultures of cells
from nonasthmatic subjects. Der p1 activity
was partially inhibited by a cysteine protease
inhibitor (CI) and by a serine protease
inhibitor (SI) naturally produced by human
lung (16,17). It was abolished by a combina-
tion of these protease inhibitors.
As previously described for GM-CSF and
RANTES release (12,13), eotaxin release
induced by Der p1 was due to increased tran-
scription from the eotaxin gene (Figure 6). 
The observation that Der p1 induces
mediator release from airway epithelial cells in
vitro is in keeping with the results of studies
demonstrating the in vivo production of GM-
CSF, RANTES, and eotaxin by the bronchial
epithelium during natural or experimental
exposure to house dust mite allergens and
other allergens in asthmatics (18–21). These
epithelial cell-derived mediators can promote
sensitization and amplify ongoing allergic
reactions. RANTES is a chemotactic factor for
dendritic cells (22) and mast cells (23). GM-
CSF enhances the ability of dendritic cells to
differentiate and present antigens effectively
and may contribute to direct the response to
house dust mite antigens toward an immune
reaction (3,5,8). Finally, RANTES, GM-CSF,
and eotaxin all upregulate eosinophil chemo-
taxis or eosinophil activation and mediator
release (21,24) (Figure 4).
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Figure 3. (A) Time-dependent migration of immunoreactive Der p1 across the monolayers of cells from allergic sub-
jects with asthma (AA), allergic subjects without asthma (A) and healthy individuals (H). Cells were cultured onto col-
lagen-coated polycarbonate ﬁlter inserts placed into the wells of 24-well culture plates and exposed to 1 µg/mL Der
p1 in the apical compartment for the indicated times. The amounts of immunoreactive Der p1 recovered in the baso-
lateral compartment of the monolayers are expressed as percentage of the starting concentration in the apical com-
partment. Der p1 immunoreactivity was evaluated by enzyme-linked immunosorbent assay (12). (B) Change in
electrical resistance from baseline under the same experimental conditions. The dashed lines indicate the range of
changes in electrical resistance detected in control monolayers exposed for the same periods of time to the diluent of
Der p1. Data are means and standard errors from 6 experiments. *p < 0.05 versus A and H; **p < 0.05 versus AA and
A; ***all p < 0.01 versus control monolayers exposed to Der p1 diluent. 
Figure 4. Schematic summary of how Der p1 and other antigens might cross the bronchial epithelium by the intracel-
lular and paracellular pathways, reach target cells within and below the epithelium, and cause sensitization and
allergic inﬂammation both directly and through the release of epithelial cell–derived mediators. Mattoli
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To investigate the mechanisms by which
Der p1 induces transcription from GM-CSF,
RANTES, and eotaxin genes in epithelial
cells, we reasoned that the promoter/enhancer
regions of these genes all contain one or more
binding sites for the nuclear factor (NF)-κ B
(18,21,25,26). We therefore tested the ability
of Der p1 to promote NF-κ B–induced gene
transcription. We found that this antigen
favors the nuclear translocation of NF-κ B
and its binding to DNA through degradation
of the NF-κ B cytoplasmic inhibitor Iκ Bα
and that Der p1-induced NF-κ B DNA-
binding activity is followed by gene transcrip-
tion with a time-course suggesting a causal
relationship (13). 
However, the effect of Der p1 on
cytokine release from airway epithelial cells
is not speciﬁc, as an allergen-induced release
of GM-CSF and IL-8 has been demon-
strated with timothy grass pollen and birch
pollen (9). Induction of cytokine release by
these antigens was not associated with any
proteolytic activity. 
Potential Effect of Antigen
Inhalation on Cardiovascular
Function
Antigen inhalation can cause an anaphylactic
reaction in sensitized individuals (27) if the
dose of antigen inhaled is sufﬁciently high or
if the level of sensitization is such that it elic-
its a generalized reaction upon exposure to
relatively low amounts of the antigen. 
However, inhaled allergens may have a
detrimental effect on cardiovascular function
by some subtler and less expected mecha-
nisms. The antigen-induced release of IL-6
from airway epithelial cells (9) may represent
one of these mechanisms. In fact, increased
concentrations of circulating IL-6 as a result
of acute and chronic airway inﬂammation are
known to induce the release of acute-phase
reactants from hepatocytes, and these in turn
induce an increase in blood viscosity and
promote thrombus formation (28,29). 
The production of endothelin-1 from
airway epithelial cells as a result of the
antigen-induced release of GM-CSF (30)
may also represent an important event affect-
ing cardiovascular function. If this peptide is
released in sufficient amounts from the air-
way epithelium to reach the circulation, it
can cause vasoconstriction and ventricular
arrhythmias (31,32). 
Issues Requiring Further
Investigation
Several aspects of antigen delivery and its
effect on the cardiovascular function need
further investigation: 
• What are the mechanisms involved in the
uptake of antigens by airway epithelial
cells? Do antigens bind to a speciﬁc recep-
tor located on the surface of airway
epithelial cells? 
•W hy are bronchial epithelial cells from
asthmatic individuals more permeable to
certain antigens than normal epithelial
cells? Does this depend on an innate or
acquired defect of the antiprotease protec-
tion system? If so, do other pathologic con-
ditions exist in which this defect can be
demonstrated or is it specific to asthma?
Because cigarette smoke reduces anti-
protease defense in the airways (16,17) and
potentiates the Der p1-induced increase in
permeability of bronchial epithelium (11),
are smokers more susceptible to antigen
sensitization than other persons? Would
treatment with antiproteases reduce the
risk of antigen sensitization? 
• What intracellular events lead to mediator
release after exposure of the airway
Figure 5. (A) Concentration-dependent release of immunoreactive eotaxin in monolayers of cells from allergic subjects with asthma (AA), allergic subjects without asthma (A),
and healthy individuals (H) after exposure to the indicated concentrations of Der p1 for 30 min and reincubation for 4 hr in the presence or absence of the cysteine protease
inhibitor (CI) E64, 10 µM, and the serine protease inhibitor (SI) α 1-antiprotease, 100 nM. (B) Time-dependent release of immunoreactive eotaxin in the same monolayers exposed
for the indicated times to 1 µg/mL Der p1. Cells were cultured onto collagen-coated polycarbonate ﬁlter inserts placed into the wells of 24-well culture plates and Der p1 was
applied to the apical compartment. Eotaxin immunoreactivity was evaluated in the culture medium by a speciﬁc radioimmunoassay (20). Der p1-induced immunoreactivity was
obtained by subtraction of the immunoreactivity detected in control monolayers exposed to the diluent of Der p1. The horizontal line indicates the detection limit of the assay (14.5
pg/mL). Data are means and standard errors from 5 experiments. *p < 0.01 versus A and H; **p < 0.001 versus cells exposed to 100 µg/mL Der p1 alone. 
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Figure 6. Demonstration of eotaxin messenger RNA
(19,20) in cultured bronchial epithelial cell monolayers of
one patient with allergic asthma exposed to the indi-
cated concentrations of Der p1 or its diluent as negative
control (C) for 30 min and reincubated for 2 hr. Positive
controls (P) were cells incubated for 4 hr with tumor
necrosis factor-α , 10 ng/mL. Total cellular RNA (1-µg
aliquots) was extracted and reverse transcribed into com-
plementary DNA. The complementary DNA was ampli-
fied by the polymerase chain reaction procedure using
upstream and downstream primers complementary to
positions 168-187 (GGGCCAGC-TTCTGTCCCAAC) and
positions 369-392 (TTATGGCTTTGGAGTTGGAGATTT) of
the 5′ and 3′ ends of the human eotaxin gene. Aliquots
of 5 µL of each resulting polymerase chain reaction
product were analyzed by Southern blot hybridization
with a [32P]UTP-labeled human eotaxin antisense ribo-
probe. The blot was exposed on X-Omat ﬁlm for 12 hr at
–70°C. The polymerase chain reaction products obtained
after amplification of the complementary DNA with
primers specific for the β -actin gene are reported to
show comparable lane loading. The data presented here
represent 3 separate experiments.
Eotaxin
β -actin
Der p1 (µg/mL)
P 0.1 1 10 CAllergen-induced airway mediators
epithelium to antigens that do not
express proteolytic activity?
• To what extent can the mediators released
by airway epithelial cells as a result of
antigen exposure affect cardiovascular
function? 
• Can antigens directly affect the cardiovas-
cular function through their enzymatic
activities once they have crossed the
epithelium and reached the circulation? 
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